TENX Shareholder Alert: Tenax Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
Notice to Pension Funds, Asset Managers, and Fiduciaries: the lawsuit alleges Tenax overstated TNX-103's clinical prospects while raising $134 million, largely through private placements, before its Phase 3 LEVEL trial missed its primary endpoint. NEW YORK, Nov. 5, 2026 /PRNewswire/ --...
Covered in this story
Call it yourself
No calls on $TENX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Tenax Therapeutics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.